Afatinib for lung cancer: let there be light?
Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCSS Istituto Nazionale dei Tumori, Via Venezian, 1 20133, 20133 Milan, Italy. Electronic address: marina.garassino@istitutotumori.mi.it.
Marina C
MC
Garassino
Laboratory of Methodology of Biomedical Research, IRCCS Mario Negri, Milan, Italy.
Valter
V
Torri
D000077716:Afatinib; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors